Therapeutic compounds for the treatment of uro-genital disorders
This a continuation of application Ser. No. 852,088, filed Nov. 16, 1977, now abandoned. 
    
    
     The present invention relates to new therapeutic compounds for the treatment of urogenital disorders. 
     In recent years, progress has been made in the non-surgical treatment of adenoma of the prostate gland, thanks notably to medicaments containing vegetable extracts of barks or of other parts of trees of the Rosaceae family, for example Asian Prunus, Prunus Africana (or Pygeum Africanum), etc . . . , (see, in particular, French patent application No. 75 16052, equivalent to British Pat. No. 1,488,838. Furthermore, the administration of certain amino acids has beneficial effects on urinary disorders such as dysuria, pollakisuria, nocturia, etc., (see, in particular, F. Damrau, Journal of the American Geriatric Society 10,  page 426 (1962) or Feinblatt and Gant in Journal of the Maine Medical Association 49, page 99 (1958)). However, the same cannot be said where diseases of the vulvo-vaginal glands, called Bartholin glands, are concerned, in particular cysts of these glands, i.e. bartholinitis. 
     This is in fact a very common illness which occurs most often in the case of young women in a period of genital activity. Although the disease is not in itself very serious, it is very troublesome because of its recurrences and because of the difficulties of a therapy which relies almost exclusively on surgical interventions and in particular on complete excision of the gland under a general anaesthetic. The operation is often very haemorrhagic, and has to be completed by rigorous haemostasia in order to avoid secondary haematomae which frequently occur. Healing is slow and painful. Moreover, the re-forming of the cyst after healing is a very frequent occurrence. 
     A similar state of affairs exists as regards cystocele or hernia of the bladder, and more particularly hernia of the bladder at the vulva, which is most often accompanied by prolapse of the uterus. This illness also causes urinary disorders (frequent and painful urination, urinary incontinence, etc.). Its treatment has also hitherto been mainly surgical. 
     Consequently, the aim of the present invention has been to provide for a new therapeutic compound which will fulfill practical needs better than previously known medicaments have done, notably in that it improves not only metabolic changes at cell level, since it is endowed with anti-inflammatory and decongestive properties and exerts therapeutic action on disorders occasioned by adenoma of the prostate and on male urinary disorders, but is also particularly active in the treatment of female uro-genital diseases such as bartholinitis and cystocele. 
     The present invention provides a new therapeutic composition which consists of a combination of an extract of plants of the Rosaceae family with monoaminated amino acids. 
     The vegetable extract is preferably constituted by extracts of Prunus Wallitchi and/or Javanica and/or Prunus Arborea and/or Prunus Lusitanica and/or Prunus Africana (or Pygeum Africanum). As stated in British Pat. No. 1,488,838, these extracts are obtained by first extracting a fraction of the plant matter with a lipid, then treating the resultant lipidic material with an alkali which reacts with the fatty acids present in the lipidic material, and then subjecting the unreacted lipidic material to solvent extraction to obtain the therapeutic extract. 
     The monoaminated amino acids are preferably selected from glycine, L-glutamic acid and L-alanine. 
     The weight ratio of vegetable extract: aminated amino acids is preferably from 1:6 to 1:25. 
     The compound according to the invention may be used in all the conventional forms of administration, e.g. in unit doses, such as tablets, soft and hard capsules, microcapsules, suppositories, liquid compounds for parenteral administration, etc. 
    
    
     The invention will be more clearly understood with reference to the description which follows and which refers to examples of preparation of unit doses of administration, as well as to reports on toxicological, pharmacological and clinical experimenting with the new compounds according to the invention. 
     It must however be clearly understood that these examples and reports on experiments are given solely by way of illustration of the subject of the invention and do not in any way constitute a restriction of the same. 
     EXAMPLES OF COMPOSITIONS 
     (1) Pharmaceutical form: soft capsules 
     One capsule contains: 
     
         ______________________________________                                    
Aminoacetic acid      45 mg                                               
L-glutamic acid       265 mg                                              
L-alanine             100 mg                                              
Extract of Prunus Arborea                                                 
                      30 mg                                               
Treatment             4 to 8 capsules                                     
                      per day.                                            
______________________________________                                    
 
    
     (2) Pharmaceutical form: hard capsules 
     One capsule contains: 
     
         ______________________________________                                    
(a) Active constituents                                                   
Extract of Pygeum Africanum                                               
                      30 mg                                               
L-glutamic acid       265 mg                                              
L-alanine             100 mg                                              
Glycine               45 mg                                               
(b) Excipients        33 mg                                               
Calcined magnesia     85 mg                                               
&#34;Aerosil&#34;®        2 mg                                                
Magnesium stearate    5 mg                                                
Treatment             4 to 9 capsules                                     
                      per day.                                            
______________________________________                                    
 
    
     BEST MODE OF PREPARATION OF THE COMPOSITIONS OF THE INVENTION 
     Following components: 
     
         ______________________________________                                    
Amino-acetic acid      675 g                                              
L-glutamic acid        3 975 g                                            
L-alanine              1 500 g                                            
&#34;AEROSIL&#34;®         30 g                                               
Magnesium stearate     75 g                                               
______________________________________                                    
 
    
     are introduced in a mixer of suitable capacity. 
     The powders are blended together. The extract of Prunus arborea is gradually added to the mixture. 
     The thus obtained mixture is granulated through a sieve, reintroduced into the mixer, sieved again, dried during 3 hours into a drying stove at 40° C. After drying, the mixture is calibrated on a sieve and distributed on a semi-automatic or similar machine. The distribution weight is 447 mg ±10 percent in hard capsules Nr 0. 
     
         ______________________________________                                    
 HARD CAPSULES                                                            
 DOSED AT 30 mg OF EXTRACT OF PRUNUS ARBOREA                              
                            for 15 000                                    
Formulation  For 1 hard capsule                                           
                            hard capsules                                 
______________________________________                                    
Total extract of                                                          
Prunus Arborea                                                            
              30 mg           450 g                                       
L-glutamic acid                                                           
             265 mg         3 975 g                                       
L-alanine    100 mg         1 500 g                                       
Amino-acetic acid                                                         
              45 mg           675 g                                       
Vehicles:                                                                 
&#34;AEROSIL&#34;®                                                            
              2 mg            30 g                                        
Magnesium stearate                                                        
              5 mg            75 g                                        
             447 mg         6 705 g                                       
______________________________________                                    
 
    
     REPORT ON PHARMACOLOGICAL EXPERIMENTS 
     (1) Toxicological study 
     A: Acute toxicity on mice (males and females weighing about 20 g) 
     
                       TABLE 1                                                     
______________________________________                                    
Doses per Kg Number of                                                    
of animal    animals        Mortality                                     
______________________________________                                    
1 g          10             0/10                                          
2 g          10             0/10                                          
3 g          10             0/10                                          
4 g          10             0/10                                          
5 g          10             0/10                                          
______________________________________                                    
 
    
     The product was administered orally in an oily suspension. Its tolerance was excellent. 
     B: Acute toxicity on rats (Adult male Wistar rats, aged over 20 months weighing 280 to 350 g) 
     
                       TABLE 2                                                     
______________________________________                                    
Doses per Kg Number of                                                    
of animal    animals        Mortality                                     
______________________________________                                    
2 g          10             0/10                                          
4 g          10             0/10                                          
6 g          10             0/10                                          
8 g          10             0/10                                          
______________________________________                                    
 
    
     The product was administered orally in an oily suspension. Its tolerance was excellent. 
     C: Short Term Chronic Toxicity 
     
         ______________________________________                                    
Length of treatment                                                       
                  52 days (by means of an                                 
                  oesophageal probe)                                      
Animals           male Wistar rats                                        
______________________________________                                    
 
    
     25 animals of the control group 
     25 animals having received 10 mg/kg of the product according to the invention, 
     25 animals having received 100 mg/kg of the product according to the invention. 
     Results: 
     The three groups of animals showed the same increase in weight--normal and continuous. There was no difference between the treated animals and the control group. On the 53rd day, when the animals had been killed, the adrenal glands, kidneys, seminal vesicles and hypophyses were extracted and weighed: there was no difference between the two groups of animals, treated and non-treated. 
     (2) Action of the compound according to the invention on the adenoma of the experimental prostate of the male rat 
     Four groups of animals, of 10 old male Wistar rats, each group from the firm Morini, were used. 
     Length of treatment: 20 days 
     Group 1: control group. 
     Group 2: treatment with the compound according to the invention: 8 mg/kg; oral administration. 
     Group 3: treatment with an extract of prostatic adenoma in a dosage of 0.5 ml per animal, subcutaneously. 
     Group 4: this group was treated 
     first preventively with the compound according to the invention in a dosage of 8 mg/kg for 30 days; then, simultaneously with this compound, the extract of prostatic adenoma was administered, in a dosage of 0.5 ml per animal per day for 20 days. 
     All the animals were killed two days after the end of treatment and the prostates, testicles and seminal vesicles were immediately removed and weighed. 
     
                       TABLE 3                                                     
______________________________________                                    
Variation of the weights in relation to the control group                 
Group   Testicles  Seminal Vesicles                                       
                                  Prostates                               
______________________________________                                    
2        0%         -4%            0%                                     
3       -6%        -18%           -15%                                    
4       -6%        -14%           -10%                                    
______________________________________                                    
 
    
     Microscopic examination of the histologic sections of the organs gave the following results: 
     Group 2: Animals treated with the compound according to the invention 
     Prostates: Epithelium having a very definite secretory activity (numerous prismatic cells). Prostatic liquid scarce, contained in small-size alveoli. Connective-tissue stroma normal. 
     Testicles: No change to the control group; normal spermatogenesis. 
     Seminal vesicles: Stimulation of the secretory epithelium, high and creased. 
     Group 3: Animals treated with extract of prostatic adenoma. 
     Prostates: In many cases, considerable cystic dilation is noted; the alveoli contain abundant and thick secretion liquid. They are bordered by a very creased epithelium, the cells frequently being undifferentiated. 
     Connective-tissue stroma only slightly modified. However, sometimes the aspect shows little difference from the normal prostate; the epithelial cells at rest border the wide alveoli, beside cells of a secretory aspect which limit the less developed alveoli. 
     Testicles: Alteration of spermatogenesis, in particular diminution of spermatozoon ripened in the light of the tubes. 
     Seminal vesicles: Fairly frequent cystic dilation, with diminution of the height of epithelial cells. 
     Group 4: Animals treated with the compound according to the invention and extract of adenoma 
     Prostates: Normal images, coexistence of small-size alveoli bordered by a pleated epithelium with high prismatic cells and more dilated alveoli limited by cubic cells. No cystic dilation. Normal connective-tissue stroma. 
     Testicles: Normal spermatogenesis, pleated secretory epithelium, fairly abundant seminal liquid. 
     Group 1: Control group 
     Prostates: Normal glandular aspect, secretory epithelium with prismatic glands, limiting the medium-sized alveoli and containing a fairly adundant secretion product, beside areas where the wider alveoli are bordered by a cubic epithelium. 
     Testicles: Normal spermatogenesis and interstitial glands. 
     Seminal vesicles: High and pleated epithelium, limiting a wide passage, with abundant seminal liquid. 
     (3) Report on Clinical Experiments 
     (a) Clinical experiments on men 
     The study concerned 70 patients divided into the following groups: 
     
         ______________________________________                                    
Group 1                                                                   
Patients suffering from confirmed prostatic hypertrophy                   
with retention               15                                           
Group 2                                                                   
Patients suffering from slight prostatic hypertrophy                      
                             20                                           
Group 3                                                                   
Patients suffering from prostatic hypertrophy with                        
alterations and vesical inflammation                                      
                             5                                            
Group 4                                                                   
Patients suffering from prostatism                                        
                             10                                           
Group 5                                                                   
Patients suffering from prostatic congestion                              
                             20                                           
______________________________________                                    
 
    
     Treatment consisted in taking daily 5 capsules such as those described in example 2 above. 
     
         ______________________________________                                    
Results:                                                                  
Group 1                                                                   
Improvement from the sixth day since taking the                           
medicament                  8 cases                                       
Improvement between the 8th and the                                       
10th day                    4 cases                                       
Improvement from the 10th day                                             
                            2 cases                                       
No improvement              1 case                                        
______________________________________                                    
 
    
     Group 2 
     At the end of 16 days of treatment, all the patients had been restored to completely normal condition. 
     Group 3 
     At the end of 10 days of treatment, improvement in prostatic symptomatology (5 out of 5 cases) as well as disappearance of cystic symptons (3 out of 5 cases) was attested. 
     Group 4 
     Some improvement in 2 of the patients after 10 days. Obvious improvement in the other 8. 
     Group 5 
     After 15 days of treatment, 18 out of 20 patients had been restored to completely normal condition. 
     (b) Clinical Experiments on Women 
     22 women suffering from bartholinitis (18) and cystocele (4) received one capsule every 8 hours for 2 months. 
     6 women suffering from bartholinitis received either the vegetable extract alone (3 women) or the aminated acids alone (3 women). 
     It was observed that the patients who had received the medicament according to the invention experienced extraordinary relief from their symptoms, even from the first days of treatment, and in some cases from the very first doses. After 2 months of treatment, there was 100% improvement in the treated women, whereas none of the 6 women of the control group showed any notable improvement. 
     The significance of the pharmacological and clinical properties of which the above is a report in that the new compounds according to the invention must be regarded as valuable medicaments both for men (prostatic adenomas, urinary disorders, chronic prostatitis, after-effects of adenectomy, etc.), and for women, in the case of whom bartholinitis has been completely cured by medication for the first time. 
     The new medicaments according to the present invention may be administered orally, parenterally or rectally, either in combination or not with appropriate vehicles and/or other medicaments.